- AOP Code: AZN 314
- Exp: 03/31/09
- Categories: Technology
- Industry: Chemical & Pharmaceutical
CRESTOR - ASTRAZENECA
Crestor is the brand name drug sold by AstraZeneca of the drug rosuvastatin calcium. It is a lipid-lowering agent for oral administration.
Patent Number: Re37,314
Latest Date for Prior Art: June 11, 1991
Filing Date of Patent: June 12, 1992
Interested Parties: IPR Pharmaceuticals, Inc.; Shionogi Seiyaku Kabushiki Kaisha; Teva Pharmaceuticals USA; Cobalt; Apotex; Par; Sandoz; Sun Pharma; Mylan; Aurobindo Pharma Ltd.; Aurobindo Pharma USA Inc.
The patent in this study is a reissue of US 5,260,444. The reissue application was filed on August 27, 1998, more than 2 years after the â€˜444 Patent issued. A reissue patent application filed more than 2 years after issuance can only seek to narrow the claims of the original patent. The only claims allowed in the reissue application were claims 6, 7 and 8. Therefore Re37,314 only covers the specific compound of claim 6 and the sodium or calcium salts thereof.
During the prosecution of the reissue application, the applicant successfully argued that the chemical composition shown in claim 6 was not anticipated or obvious. A copy of the imaged filewrapper is available on the USPTO website. You can access the filewrapper by using the PAIR function at the USPTO site.
The chemical name for rosuvastatin calcium is bis[(E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino] pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid] calcium salt.
All references need to have been published on or before this date. Any references published after the LDPA will be automatically declined.
Specific claims or technical disclosures on which the scope of the Study is based. Your submissions should be based on these requirements.